[Upadacitinib (atopic dermatitis) - Benefit assessment according to ยง35a Social Code Book V]

Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018004006
Original Title: Upadacitinib (atopische Dermatitis)
Project Status: Completed
Year Published: 2021
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
MeSH Terms
  • Dermatitis, Atopic
  • Janus Kinase Inhibitors
  • Upadacitinib
  • Dermatitis - Atopic
  • Benefit Assessment
  • NCT03738397
  • NCT03569293
  • NCT03607422
  • NCT03568318
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: <p>Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.